CIBC World Markets Ups Randgold-Resources (NDAQ:GOLD) To Sector Outperform from Sector Perform; Profile of 4 Analysts Covering CARDIOME PHARMA (CRME)

Among 4 analysts covering Randgold-Resources (NDAQ:GOLD), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Randgold-Resources has $136 highest and $4.50 lowest target. $70.25’s average target is -21.19% below currents $89.14 stock price. Randgold-Resources had 4 analyst reports since March 8, 2017 according to SRatingsIntel. The firm earned “Underperform” rating on Wednesday, March 8 by RBC Capital Markets. Deutsche Bank downgraded the stock to “Hold” rating in Friday, March 17 report.

Among 5 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cardiome Pharma Corp had 8 analyst reports since August 11, 2015 according to SRatingsIntel. The company was downgraded on Tuesday, August 11 by Zacks. The firm has “Buy” rating by Brean Capital given on Friday, March 11. The company was downgraded on Wednesday, August 26 by Zacks. The stock has “Hold” rating by Mackie on Wednesday, October 12. H.C. Wainwright initiated CARDIOME PHARMA CORP (NASDAQ:CRME) on Wednesday, June 1 with “Buy” rating. The firm earned “Buy” rating on Friday, August 14 by LB Securities. Leerink Swann initiated the stock with “Outperform” rating in Thursday, December 22 report. The firm has “Speculative Buy” rating given on Friday, May 6 by Mackie. See CARDIOME PHARMA CORP (NASDAQ:CRME) latest ratings:

22/12/2016 Broker: Leerink Swann Rating: Outperform Initiate

About 42,100 shares traded. CARDIOME PHARMA CORP (NASDAQ:CRME) has risen 5.70% since September 28, 2016 and is uptrending. It has underperformed by 4.35% the S&P500.

Cardiome Pharma Corp. is a specialty pharmaceutical company. The company has market cap of $102.85 million. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. It currently has negative earnings. The Company’s divisions are Europe and Rest of World.

Investors sentiment decreased to 0.91 in Q4 2016. Its down 1.80, from 2.71 in 2016Q3. It dived, as 2 investors sold CARDIOME PHARMA CORP shares while 9 reduced holdings. 5 funds opened positions while 5 raised stakes. 14.48 million shares or 7.43% less from 15.64 million shares in 2016Q3 were reported. Group One Trading L P reported 10,670 shares or 0% of all its holdings. Blackrock Institutional Trust Company Na holds 3,184 shares. Morgan Stanley reported 32,703 shares. Wells Fargo & Company Mn holds 0% in CARDIOME PHARMA CORP (NASDAQ:CRME) or 800 shares. Geode Capital Mgmt Ltd Liability Company holds 13,180 shares or 0% of its portfolio. Savings Bank Of America Corp De accumulated 0% or 45 shares. Citadel Advsrs Limited Liability Corp owns 28,308 shares. Bankshares Of Montreal Can has 0% invested in CARDIOME PHARMA CORP (NASDAQ:CRME) for 6,752 shares. The Massachusetts-based Clough Ptnrs Limited Partnership has invested 0.56% in CARDIOME PHARMA CORP (NASDAQ:CRME). Deutsche Commercial Bank Ag holds 500 shares. Sabby Mngmt Limited Liability owns 437,720 shares or 0.07% of their US portfolio. Alphaone Inv Serv Limited Liability has invested 0.42% in CARDIOME PHARMA CORP (NASDAQ:CRME). Renaissance Technologies Ltd Llc invested 0% in CARDIOME PHARMA CORP (NASDAQ:CRME). Walleye Trading Limited Liability Corp has 0% invested in CARDIOME PHARMA CORP (NASDAQ:CRME) for 3,900 shares. Moreover, Jpmorgan Chase & has 0% invested in CARDIOME PHARMA CORP (NASDAQ:CRME) for 54,897 shares.

About 950,600 shares traded or 37.21% up from the average. Randgold Resources Ltd. (ADR) (NDAQ:GOLD) has declined 17.57% since September 28, 2016 and is downtrending. It has underperformed by 27.62% the S&P500.

Randgold Resources Limited is engaged in gold mining, exploration and related activities. The company has market cap of $8.37 billion. The Company’s activities are focused on West and Central Africa. It has a 32.25 P/E ratio. The Firm operates through the gold mining segment.